Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, Yesterday

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.

Current smoking ups death, hospitalization in HFpEF patients

12 Sep 2018

Current smoking increases the likelihood of adverse outcomes in patients with heart failure with preserved ejection fraction (HFpEF), a recent study has shown.

Researchers analysed 1,717 patients with HFpEF (mean age 71±10 years; 50 percent male), most of whom (51 percent; n=871) were former smokers. Seven percent (n=116) and 42 percent (n=729) were current and never smokers, respectively.

Over a median follow-up period of 2.9 years, researchers observed 387 hospitalizations for heart failure. Cox regression analysis showed that compared with former smokers, current smokers were significantly more likely to be hospitalized for heart failure (hazard ratio [HR], 1.68; 95 percent CI, 1.08–2.61; p=0.02).

In the same time span, there were 374 deaths recorded, majority of which (n=218) were cardiovascular in nature. Relative to never smoking, current smoking was likewise associated with significantly higher risks of death (HR, 1.82; 1.19–2.78; p=0.0057) and cardiovascular death (HR, 1.85; 1.09–3.14; p=0.022).

No such effect was observed for former smoking compared with never smoking (hospitalization for heart failure: HR, 1.25; 0.99–1.57; p=0.053; death: HR, 1.02; 0.81–1.29; p=0.85; cardiovascular death: HR, 1.00; 0.74–1.35; p=0.99).

Analyses were adjusted for age, sex, race, body mass index, aspirin and antihypertensive medication use, systolic blood pressure, and comorbidities such as diabetes, chronic obstructive pulmonary disease, stroke and coronary heart disease.

Though further studies are needed to confirm these findings, the present results suggest that smoking cessation programmes may be beneficial to HFpEF patients, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, Yesterday

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.